Loading stock data…
IMA
$5.66-0.35 (-5.82%)
Market ClosedLast close May 1
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImageneBio, Inc. in the Healthcare sector is trading at $5.66. The stock is currently near its 52-week low of $3.94, remaining 31.9% below its 200-day moving average. Technical signals show neutral RSI of 41 and bullish MACD crossover, explaining why IMA maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.66
Potential Upside
5%
Whystock Fair Value$5.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$65.54M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.06%
Volume
Today's trading volume
109,691
Recent News
Image Resources NL (ASX:IMA) Is About To Turn The Corner
With the business potentially at an important milestone, we thought we'd take a closer look at Image Resources NL's...
Imax announces $28M opening weekend for Amazon/MGM/s ‘Project Hail Mary’
IMAX (IMAX) Corporation announces the opening weekend for Amazon (AMZN) / MGM Studies’ “Project Hail Mary,” with IMAX delivering $28M at the global box office. The latest Filmed For IMAX release from Amazon/MGM, “Project Hail Mary” delivered $16.4 million in IMAX at the Domestic box office – 20% of the film’s North American debut on just 1% of screens in the market. “‘Project Hail Mary’ is an excellent film for which Amazon/MGM ran a brilliant campaign, leaning heavily on the power of IMAX as a
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap
ImageneBio, Inc. ( NASDAQ:IMA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
The consensus price target hints at a 695.5% upside potential for IMAGENEBIO INC (IMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.